信立泰(002294.SZ):擬以8000萬美元向諾泰增資 用於其新設子公司收購併增資美國Salubris
格隆匯 3 月 30日丨信立泰(002294.SZ)公佈,根據公司境外子公司戰略發展規劃,公司擬以自有資金8000萬美元(或等值其他幣種,約合港幣62117.65萬元,以實際投資時匯率折算額為準),向香港全資子公司諾泰國際有限公司(“諾泰”)增資。增資款將用於諾泰對外投資新設子公司;前述子公司設立完成後,將由新設公司以前述資金收購公司全資子公司信立泰(成都)生物技術有限公司持有的Salubris Biotherapeutics, Inc.(“美國Salubris”)100%股權;並對Salubris Biotherapeutics, Inc.增資,增資款用於美國Salubris日常經營研發。其中,收購股權金額為30648.49萬元人民幣(或等值其他幣種),剩餘資金用於向美國Salubris增資。
對諾泰的增資完成後,公司對諾泰的投資總額將由33833.13萬港幣增至95950.78萬港幣(最終以實際投資時匯率折算額為準)。諾泰仍為公司全資子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.